Brain damage that can occur before, during, or after delivery combined with permanent movementand postural deficit results in cerebral palsy (CP). CP affects physical characteristics like limbs,physiological and mental processes, as well as actions like standing and walking (e.g., sports).These shortcomings ultimately result in a number of disabilities, including deficits, restrictedmovement, and participation. Kinesio taping (KT) is a relatively new therapeutic techniqueused in the rehabilitation facility for children with cerebral palsy, however, it has been usedfor a long time in the sports or orthopedic domains and has been approved as adjuvant therapyfor another functional handicap. Comparing CP treatment with PNF strength, PNF stretch, andPNF stretch alone will help spastic diplegic patients receive better care. The participants fromthe OPD and pediatric physiotherapy department of Shri Guru Ram Rai Institute of Medical andHealth Sciences & Shri Mahant Indresh Hospital, Patel Nagar, Dehradun, were randomly splitinto two groups, with one receiving PNF stretching and the other receiving Kinesio-taping (n =15 in each group). The interventions were given to both groups three days a week for a total of12 weeks. Kinesio-taping along with PNF and PNF stretching alone both showed improvementin ankle dorsiflexion in spastic diplegic children but Kinesio-taping along with PNF showedmore improvement in ankle dorsiflexion function in reducing calf muscle tightness and alsoimprove walking pattern of the child after 12 weeks of intervention.

most common kind of cerebral palsy, called spastic diplegic cerebral palsy. Some of theusual symptoms include muscular weakness, poor muscle coordination, poor balance, loss ofpostural control, and postural misalignment. The issue is not confined to physical restrictionswhen a person has poor postural instability that makes walking challenging; instead, theperson has increasing psychological challenges and problems. For this study, 30 children withSDCP from the pediatrics physiotherapy OPD and IPD departments at the Shri Guru RamRai Institute of Medical Science and Shri Mahant Indresh Hospital in Patel Nagar, Dehradun,were chosen. For testing, children were randomly split into two groups: one group of 15 kidsreceived standard care alone, while the other group of 15 kids received standard care with theVestibular Stimulation Technique. When the data from both groups are evaluated, there was asignificant difference between them, however group A shows more development. The findingsof the analysis of the data from the PBS and MAS outcome measures are the same for bothoutcome measures. From the data collected it was suggested that the patients will probablyhave benefited more after four weeks of treatment with VST plus conventional therapy thanif conventional therapy were administered alone. Although vestibular stimulation paired withconventional therapy demonstrated a more obvious improvement in clinical results for trunkcontrol, both therapies were proven to significantly improve trunk control of balance.

AIMS:Denosumab is a fully human monoclonal immunoglobulin G2 antibody that inhibits bone resorption and increases bone mass and strength. The present clinical study assessed serum and seminal fluid pharmacokinetics following a single denosumab dose in healthy men, and evaluated whether denosumab in seminal fluid poses any risk to a fetus in the event of unprotected sexual intercourse with a pregnant partner.METHODS:An open-label, single-dose study in 12 healthy men was conducted over a 106-day period. Subjects received a single subcutaneous dose of 60-mg denosumab on day 1. Serum and seminal fluid samples were collected at specified time points to assess denosumab pharmacokinetics. Adverse events were recorded.RESULTS:Denosumab was measurable at low concentrations in seminal fluid (~2% of serum concentrations). The mean [standard deviation (SD)] maximum observed drug concentration (Cmax ) was 6170 (2070) ng ml(-1) (serum) and 100 (81.9) ng ml(-1) (seminal fluid). The median time to Cmax (tmax ) was 8 days (serum) and 21 days (seminal fluid). The mean (SD) area under the plasma concentration-time curve (AUC) from time zero to the time of the last quantifiable concentration (AUClast ) was 333 000 (122 000) day•ng ml(-1) (serum) and 5220 (4880) day•ng ml(-1) (seminal fluid). The mean (SD) Cmax and AUC ratios between seminal fluid and serum were 0.0217 (0.0154) and 0.0170 (0.0148), respectively. Using conservative assumptions for ejaculate volume (6 ml), vaginal absorption (100%) and placental transfer (100%), the measured mean denosumab seminal fluid Cmax would result in fetal exposure that was more than 110 times below the preclinically derived 'no effect level' for denosumab.CONCLUSIONS:These results indicate a negligible risk to a fetus exposed to denosumab via seminal fluid transfer to a pregnant partner.